Switzerland · Delayed Price · Currency is CHF Sonova Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Delivered strong sales and profit growth, driven by innovation and market share gains in hearing instruments and retail, while cochlear implants faced headwinds. Outlook for 2026-2027 is positive, with continued above-market growth and margin expansion expected.
-
A refreshed strategy aims for CHF 6 billion revenue by FY 2031, focusing on hearing care, innovation, and operational excellence. Growth will be driven by market share gains, Asia expansion, and disciplined M&A, with midterm targets of 5%-10% sales CAGR and 7%-12% core EBIT CAGR.
-
Sales grew 4.9% in local currencies, with strong gains in hearing instruments and audiological care, offsetting weakness in consumer hearing and cochlear implants. Guidance for 5-9% sales growth and 14-18% EBITDA growth is reiterated, supported by new product launches and operational improvements.
Fiscal Year 2025
-
Solid full-year growth was achieved across all segments, with strong market share gains and improved profitability driven by product innovation and structural cost reductions. Guidance for FY25 anticipates 5%-9% sales growth and further margin expansion, despite macroeconomic and tariff headwinds.
-
Sales grew 5.9% in local currencies, led by hearing instruments and cochlear implants, despite market headwinds and higher launch costs. Strong momentum from new product launches is expected to drive margin expansion and improved profitability in the second half, with full-year guidance confirmed.
Fiscal Year 2024
-
The company reaffirmed its mid-term growth and EBITDA targets, driven by the launch of the Infinio and Sphere Infinio platforms, which feature breakthrough AI technology for speech clarity. Early US demand for Sphere exceeded expectations, with European rollout set for September. Operational improvements and brand consolidation continue to support growth.